(Q71854367)

English

Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients

scientific article published on 01 January 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

colorectal cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Andrea Nicolini

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

author name string

Mancini PA

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Ferrari P

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Anselmi L

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Sagripanti A

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Carpi A

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

publication date

1 January 1996

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Biomedicine and Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

50

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

344-349

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 2 therapy in cancer: identification of responders

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 in cancer treatment: disappointing or (still) promising? A review

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0753-3322%2896%2989666-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0753-3322(96)89666-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8952853%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q71854367&oldid=2137691459"